Clinical Trial Search

Primary: Progression Free Survival (PFS) — 1.8; 3.7 months — p=.04

Primary: System Usability Scale (SUS) — 90.6 score on a scale

Primary: Change in Epigenetic Markers — 84.4; 82.8 years

Primary: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) — 7; 5; 5; 7 Participants

Primary: Percentage of Participants With At Least One Treatment-Emergent Adverse Event (TEAE) Leading to Dose Interruption/Discontinuation — 7.1 percentage of participants

Primary: Number of Participants With Clinically Significant Structural Brain Change on T1- and T2-weighted Magnetic Resonance Imaging (MRI) — 0 Participants

Primary: Estimate of the 14-day Early Bactericidal Activity (EBA), Based on Colony Forming Unit Counts, of the Combination of Meropenem and Amoxicillin/Clavulanate, Without…

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 10; 8; 7; 8 Participants

Primary: HIV-1 RNA at Week 24 — 25 Participants

Primary: Signs and Symptoms: Mean DAS28 Post Baseline — 3.26; 3.62; 3.06; 3.42 score on a scale — p=<0.0001

Primary: Treatment Session Adherence Rate — 7.88; 8 Number of sessions attended

Primary: Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S…

Primary: Number of Pediatric Patients With a Positive Exome Sequencing Result — 142 Participants

Primary: Change in Endothelial Progenitor Cells — -10.01; 5.19 Percentage of EPCs

Primary: Change in Body Weight (%) — -6.1; -6.9; -8.5; -9.5 Percentage point of body weight — p=0.0002